Cite
HARVARD Citation
Hegewisch-Becker, S. et al. (2015). Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Lancet oncology. 16 (13), pp. 1355-1369. [Online].